Literature DB >> 10527208

Effectiveness of preoperative transarterial chemoembolization in presumed inoperable hepatoblastoma.

Y M Han1, H H Park, J M Lee, J C Kim, P H Hwang, D K Lee, C S Kim, K C Choi.   

Abstract

PURPOSE: To evaluate the effectiveness and therapeutic role of preoperative transarterial chemoembolization (TACE) of hepatoblastoma.
MATERIALS AND METHODS: Four patients (one boy, three girls) with unresectable hepatoblastoma were treated twice with preoperative TACE in an effort to improve the surgical and clinical outcome. The patients ranged in age from 8 to 27 months (mean, 15 months). The first TACE was performed superselectively in tumor feeding arteries. The second TACE was performed 3 weeks later. Surgical hepatic resection was performed 1 month after the second TACE. Contrast-enhanced computed tomography (CT) was used to evaluate changes in size, volume, internal texture, and margin of the masses. The toxicity of the chemotherapeutic drugs was evaluated by blood chemistry analysis (AST/ALT, alpha-FP) performed before and after TACE, and after surgery.
RESULTS: TACE allowed subsequent surgical resection in all four patients, who remained disease free 16-52 months after operation. There were no major problems related to TACE. There was no chemotherapeutic agent toxicity from TACE. The average largest diameters and volumes of the tumors decreased by 31% (8.3 to 5.6 cm) and 69% (317 to 93 cm2), respectively.
CONCLUSION: TACE provided subsequent successful surgical resection and good long-term results in all four patients. The hepatoblastomas were initially considered inoperable because of extensive hepatic involvement and indistinct margins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527208     DOI: 10.1016/s1051-0443(99)70231-9

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  3 in total

1.  Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma.

Authors:  Weiguang Xu; Jung-Hee Kwon; Young Ho Moon; Young Bae Kim; Yun Suk Yu; Namgyu Lee; Kwan Yong Choi; Yun Soo Kim; Yong Keun Park; Bong Wan Kim; Hee Jung Wang
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-23       Impact factor: 4.553

2.  Hepatocellular carcinoma: clinical study of long-term survival and choice of treatment modalities.

Authors:  Ke-Tong Wu; Cun-Chuan Wang; Li-Gong Lu; Wei-Dong Zhang; Fu-Jun Zhang; Feng Shi; Chuan-Xing Li
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

3.  Hepatoblastoma: a single institutional experience of 18 cases.

Authors:  Parul J Shukla; Savio G Barreto; Sajid S Qureshi; Rohini Hawaldar; Shailesh V Shrikhande; Mukta R Ramadwar; Shripad Banavali
Journal:  Pediatr Surg Int       Date:  2008-05-06       Impact factor: 1.827

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.